Leveraging metabolism for better outcomes in heart failure

• Published in: Cardiovascular research 2024-12, Vol.120 (15), p.1835-1850
• Main Authors: Ng, Yann Huey, Koay, Yen Chin, Marques, Francine Z, Kaye, David M, O'Sullivan, John F
• Format: Article
• Language: English
• Subjects: Animals; Energy Metabolism - drug effects; Heart Failure - diagnosis; Heart Failure - drug therapy; Heart Failure - metabolism; Heart Failure - physiopathology; Humans; Invited Review; Metabolomics; Mitochondria, Heart - drug effects; Mitochondria, Heart - metabolism; Mitochondria, Heart - pathology; Myocardium - metabolism; Myocardium - pathology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Treatment Outcome
• ISSN: 0008-6363; 1755-3245; 1755-3245
• DOI: 10.1093/cvr/cvae216

Whilst metabolic inflexibility and substrate constraint have been observed in heart failure for many years, their exact causal role remains controversial. In parallel, many of our fundamental assumptions about cardiac fuel use are now being challenged like never before. For example, the emergence of sodium-glucose cotransporter 2 inhibitor therapy as one of the four 'pillars' of heart failure therapy is causing a revisit of metabolism as a key mechanism and therapeutic target in heart failure. Improvements in the field of cardiac metabolomics will lead to a far more granular understanding of the mechanisms underpinning normal and abnormal human cardiac fuel use, an appreciation of drug action, and novel therapeutic strategies. Technological advances and expanding biorepositories offer exciting opportunities to elucidate the novel aspects of these metabolic mechanisms. Methodologic advances include comprehensive and accurate substrate quantitation such as metabolomics and stable-isotope fluxomics, improved access to arterio-venous blood samples across the heart to determine fuel consumption and energy conversion, high quality cardiac tissue biopsies, biochemical analytics, and informatics. Pairing these technologies with recent discoveries in epigenetic regulation, mitochondrial dynamics, and organ-microbiome metabolic crosstalk will garner critical mechanistic insights in heart failure. In this state-of-the-art review, we focus on new metabolic insights, with an eye on emerging metabolic strategies for heart failure. Our synthesis of the field will be valuable for a diverse audience with an interest in cardiac metabolism.